News

6 October 2017

TBDO Sessions Lluís Armengol/Ruth Muñoz/Luis Ruiz/Leandro Vetcher

06/10/201710:00RAMÓN Y CAJALTBDO SessionsLluís Armengol/Ruth Muñoz/Luis Ruiz/Leandro VetcherCSO and CEO of qGenomics/CSO of Leukos Biotech/CEO at Spherium Biomed/Director of Harvard’s Blavatnik Biomedical AcceleratorRound Table discussion in the context of the 4th CRG BioBusiness School.Host: Cironi López, PabloAbstract:These four seasoned and new entrepreneurs in the biotech sector will share their motivations to become entrepreneurs, and experiences in doing so.

2 October 2017

a href=https://www.crg.eu/en/event/tbdo-sessions-andr%C3%A9s-g-fern%C3%A1ndezTBDO Sessions Andrés G. Fernández/a

pspan class=body_102/10/2017/spanspan class=body_209:30/spanspan class=body_3CHARLES DARWIN/spanspan class=body_4TBDO Sessions/spanspan class=body_5Andrés G. Fernández/spanspan class=body_6Ferrer Advanced Biotherapeutics/spanspan class=body_7Biopharma industry: Decision process on project selection and investment prioritization/spanspan class=body_8Host: Cironi López, Pablo/spanspan class=body_9Abstract:/spanAs Director of Ferrer Advanced Biotherapeutics, the Biotech Research Division of Ferrer International, Andrés G. Fernández and his team work to actively identify and select high added-value biopharmaceutical projects that they help to transform into real products in a variety of therapeutic and diagnostic areas. Previous to his current position, Andrés held a number of executive and scientific responsibilities at Ferrer, Almirall andbr / Salvat laboratories, where he helped to successfully develop and launch an important.../p
2 October 2017

TBDO Sessions Andrés G. Fernández

02/10/201709:30CHARLES DARWINTBDO SessionsAndrés G. FernándezFerrer Advanced Biotherapeutics"Biopharma industry: Decision process on project selection and investment prioritization"Host: Cironi López, PabloAbstract:As Director of Ferrer Advanced Biotherapeutics, the Biotech Research Division of Ferrer International, Andrés G. Fernández and his team work to actively identify and select high added-value biopharmaceutical projects that they help to transform into real products in a variety of therapeutic and diagnostic areas. Previous to his current position, Andrés held a number of executive and scientific responsibilities at Ferrer, Almirall and
Salvat laboratories, where he helped to successfully develop and launch an important...

2 October 2017

TBDO Sessions Andrés G. Fernández

02/10/201709:30CHARLES DARWINTBDO SessionsAndrés G. FernándezFerrer Advanced Biotherapeutics"Biopharma industry: Decision process on project selection and investment prioritization"Host: Cironi López, PabloAbstract:As Director of Ferrer Advanced Biotherapeutics, the Biotech Research Division of Ferrer International, Andrés G. Fernández and his team work to actively identify and select high added-value biopharmaceutical projects that they help to transform into real products in a variety of therapeutic and diagnostic areas. Previous to his current position, Andrés held a number of executive and scientific responsibilities at Ferrer, Almirall and
Salvat laboratories, where he helped to successfully develop and launch an important...

6 September 2017

This one goes up to 11: researchers crack code for genetic ‘control dials’

CRG scientists develop a new technique to crack the underlying DNA code for the ‘control dials’ that determine levels of gene activity in bacteria.

1 August 2017

CaixaImpulse funds a project to develop a new cancer treatment based in aternative splicing

The AON project aims to develop new cancer treatment for lung adenocarcinoma based on antisense oligonucleotides acting selectively on key cancer related genes.

5 July 2017

An experimental technique analyses for the first time the functioning of human sperm before being inseminated into the egg

The work of the CRG and Eugin Group succeeds in observing the fertilisation capacity of the sperm cell before its insemination in the oocyte.

28 June 2017

The TBDO participated in the 2017 BIO International Convention in San Diego

The BIO International Convention (BIO) attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. 

Read More

5 May 2017

PRBB-CRG Sessions Ricardo Macarrón

05/05/201712:00MARIE CURIEPRBB-CRG SessionsRicardo MacarrónEMTM, PhD, VP of Target and Pathway Validation, Target Sciences, GlaxoSmithKline- R&D, USA“Targets and leads: the complex world of drug discovery. Science in innovative companies: this is not the dark side”Host: Juan Valcárcel (CRG) and Pablo Cironi (CRG)